全文获取类型
收费全文 | 67200篇 |
免费 | 6254篇 |
国内免费 | 2605篇 |
专业分类
耳鼻咽喉 | 741篇 |
儿科学 | 1610篇 |
妇产科学 | 1237篇 |
基础医学 | 7072篇 |
口腔科学 | 1413篇 |
临床医学 | 6177篇 |
内科学 | 6213篇 |
皮肤病学 | 1251篇 |
神经病学 | 2375篇 |
特种医学 | 3531篇 |
外国民族医学 | 62篇 |
外科学 | 8333篇 |
综合类 | 11466篇 |
现状与发展 | 21篇 |
预防医学 | 1806篇 |
眼科学 | 746篇 |
药学 | 4582篇 |
47篇 | |
中国医学 | 2001篇 |
肿瘤学 | 15375篇 |
出版年
2024年 | 63篇 |
2023年 | 962篇 |
2022年 | 1488篇 |
2021年 | 2646篇 |
2020年 | 2360篇 |
2019年 | 2120篇 |
2018年 | 1977篇 |
2017年 | 2249篇 |
2016年 | 2531篇 |
2015年 | 2727篇 |
2014年 | 4136篇 |
2013年 | 4261篇 |
2012年 | 3744篇 |
2011年 | 4184篇 |
2010年 | 3361篇 |
2009年 | 3372篇 |
2008年 | 3390篇 |
2007年 | 3654篇 |
2006年 | 3301篇 |
2005年 | 2969篇 |
2004年 | 2573篇 |
2003年 | 2202篇 |
2002年 | 2028篇 |
2001年 | 1825篇 |
2000年 | 1501篇 |
1999年 | 1342篇 |
1998年 | 1109篇 |
1997年 | 981篇 |
1996年 | 863篇 |
1995年 | 876篇 |
1994年 | 753篇 |
1993年 | 602篇 |
1992年 | 515篇 |
1991年 | 463篇 |
1990年 | 359篇 |
1989年 | 338篇 |
1988年 | 311篇 |
1987年 | 264篇 |
1986年 | 211篇 |
1985年 | 253篇 |
1984年 | 234篇 |
1983年 | 155篇 |
1982年 | 186篇 |
1981年 | 155篇 |
1980年 | 123篇 |
1979年 | 106篇 |
1978年 | 74篇 |
1977年 | 62篇 |
1976年 | 51篇 |
1975年 | 18篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
3.
外泌体是一类直径为30~100 nm的圆盘囊泡,其内包含许多组分,诸如复杂RNA和蛋白质等,主要参与细胞间的信号转导。肿瘤相关巨噬细胞(tumor-associated macrophages,TAMs)是肿瘤微环境中普遍存在的巨噬细胞,通过对肿瘤生长、免疫逃逸、侵袭和转移、耐药性等多方面的作用影响肿瘤进程。外泌体在肿瘤相关巨噬细胞的招募、极化及抗肿瘤免疫调控等方面发挥着重要的调节功能。同时,TAMs以外泌体为媒介作用于肿瘤细胞,从而构成了外泌体、TAMs与肿瘤细胞之间相互作用的调控通路。综上所述,本文旨在阐明肿瘤细胞与TAMs之间,以外泌体为“桥梁”相互影响的潜在机制,以及靶向肿瘤细胞和TAMs来源的外泌体在恶性肿瘤治疗中的展望。 相似文献
4.
5.
BackgroundCentrally located pancreatic lesions are often treated with extended pancreaticoduodenectomy or distal pancreatectomy resulting in loss of healthy parenchyma and a high risk of diabetes and exocrine insufficiency. Robotic central pancreatectomy (RCP) is a parenchyma sparring alternative that has been shown safe and feasible [[1], [2]].MethodsIn this article, we describe our operative technique and the perioperative outcomes of a series of RCP for low-grade or benign pancreatic tumors.ResultsSix patients (5 female and 1 man) with a median age of 51.5 (44–68) years underwent a RCP for 2 serous cystadenomas, 2 mucinous cystic tumors, 1 neuroendocrine tumor, and 1 autoimmune pancreatitis. There were no conversions, intraoperative complications, or perioperative transfusions. Median operative time and was 240 (230–291) minutes and median blood loss was 100 (100–400) ml. The median hospital stay was 8 (5–27) days. There were no mortalities, reoperations, or readmissions. One patient developed a grade B pancreatic fistula which was successfully managed conservatively. All resections had free margins and the median tumor size was 2.5 (1.5–3.5) cm. After a mean follow-up of 46 months, no patients presented new-onset diabetes or exocrine insufficiency.ConclusionsRCP represents the least invasive option for both the patient and the pancreatic parenchyma. With a standardized technique, RCP results in low postoperative morbidity and excellent long-term pancreatic function. Although our results are excellent, POPF still represents the main complication of central pancreatectomy with an incidence ranging from 0 to 80% depending on multiple factors such as the surgeon, technique, and pancreatic texture. 相似文献
6.
Xi Tian Yue Wang Wenhao Xu Haidan Tang Shuxuan Zhu Aihetaimujiang Anwaier Wangrui Liu Wenfeng Wang Wenkai Zhu Jiaqi Su Yuanyuan Qu Hailiang Zhang Dingwei Ye 《International journal of cancer. Journal international du cancer》2023,152(1):66-78
In clear cell renal cell carcinoma (ccRCC), glycolysis is enhanced mainly because of the increased expression of key enzymes in glycolysis. Hence, the discovery of new molecular biomarkers for glycolysis may help guide and establish a precise system of diagnosis and treatment for ccRCC. Expression profiles of 1079 tumor samples of ccRCC patients (including 311 patients treated with everolimus or nivolumab) were downloaded from public databases. Proteomic profiles of 232 ccRCC samples were obtained from Fudan University Shanghai Cancer Center (FUSCC). Biological changes, tumor microenvironment and prognostic differences were explored between samples with various glycolysis characteristics. There were significant differences in CD8+ effector T cells, epithelial-to-mesenchymal transition and pan-fibroblast TGFb between the Low and High glyScore groups. The tumor mutation burden of the Low glyScore group was lower than that of the High glyScore group. And higher glyScore was significantly associated with worse overall survival (OS) in 768 ccRCC patients (P < .0001). External validation in FUSCC cohort also indicated that glyScore was of strong ability for predicting OS (P < .05). GlyScore may serve as a biomarker for predicting everolimus response in ccRCC patients due to its significant associations with progression-free survival (PFS). And glyScore may also predict overall survival in patients treated with nivolumab. We calculated the glyScore in ccRCC and the defined glyScore was of strong ability for predicting OS. In addition, glyScore may also serve as a biomarker for predicting PFS in patients treated with everolimus and could predict OS in patients treated with nivolumab. 相似文献
7.
8.
《Clinical lung cancer》2022,23(3):191-194
BackgroundTo accelerate drug approvals while maintaining scientific rigor in the evaluation of a therapeutic's efficacy and safety, the United States Food and Drug Administration now considers real-world data (RWD) to support New Drug Applications and expanded indications. Response Evaluation Criteria in Solid Tumors (RECIST) are the gold standard in clinical trials, but the derivation of RECIST-based treatment response from RWD is unproven. This study investigated the feasibility of implementing RECIST criteria in RWD by comparing lung cancer response assessments from RECIST-based measurement of lesions on archived radiologic films with results from medical oncologist and radiologist narratives recorded in electronic health records (EHR).Materials and MethodsResponse to index treatment via different assessment approaches was compared among 30 metastatic non-small cell lung cancer (mNSCLC) patients receiving systemic treatment (index) after progression on a platinum or anti-PD(L)-1-containing regimen. Specifically, responses based on assessments documented in the medical oncologists’ narratives were compared to a radiologist's assessments of archived images using RECIST v1.1 criteria. Each patient's best overall response was characterized as complete or partial (CR/PR), stable disease (SD), progressive disease (PD), or not evaluable (NE).ResultsSimilar distributions of best overall response and substantial concordance (77%) between medical oncologist-reported and radiologist re-assessed responses were observed. There were no instances of CR/PR to PD or PD to CR/PR discordance.ConclusionsResults suggest that accurate treatment responses, similar to RECIST, may be derived using RWD. Further validation and improvement of real-world response assessment are needed to develop a scalable real-world approach for response assessment. 相似文献
9.
10.
目的:探究三结构域蛋白59(TRIM59)调控人皮肤黑色素瘤细胞SK-MEL-2增殖、细胞周期、凋亡及迁移侵袭的作用机制,及其与Bcl2相关转录因子1(BCLAF1)之间的关系。方法:qPCR和WB法检测人表皮黑色素细胞HEMn-LP、人皮肤黑色素瘤细胞SK-MEL-2、UACC903、A375及36例邢台市人民医院2019年2月至2021年7月收集的皮肤黑色素瘤组织中TRIM59的mRNA和蛋白表达,使用脂质体将si-con、si-TRIM59转染至SK-MEL-2细胞中,WB法检测干扰TRIM59表达对细胞中周期蛋白D1(CCND1)、细胞周期素依赖性激酶2(CDK2)、肿瘤抑制蛋白基因(TP53)和 BCLAF1 蛋白表达的影响,CCK-8法、流式细胞术、划痕愈合实验、Transwell实验检测对细胞的活性、凋亡、迁移和侵袭的影响,免疫共沉淀(Co-IP)实验检测对细胞中TRIM59蛋白与BCLAF1结合能力的影响。结果:与HEMn-LP细胞相比,SK-MEL-2、UACC903、A375细胞中TRIM59 mRNA和TRIM59、BCLAF1蛋白均呈高表达(均P<0.05),SK-MEL-2细胞中TRIM59表达水平最高。相较于si-con组和Normal组,沉默TRIM59后,SK-MEL-2细胞的活性显著降低,细胞周期阻滞于G2期,CCND1、CDK2的蛋白表达显著降低,TP53蛋白和细胞凋亡率均显著升高,划痕抑制率明显升高,迁移侵袭细胞数明显降低(均P<0.05)。免疫共沉淀实验结果显示,TRIM59与BCLAF1之间存在蛋白结合关系。TRIM59与 BCLAF1 在肿瘤组织中的表达呈显著的正相关(r=0.878,P<0.001)。结论:干扰TRIM59表达能够抑制人皮肤黑色素瘤SK-MEL-2细胞的增殖、迁移和侵袭而促进凋亡,抑制SK-MEL-2细胞的恶性生物学行为,其机制可能与TRIM59结合BCLAF1有关。 相似文献